alpha biomed tirzepatide Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), positively impacts the altered microbiota of obese, diabetic, ovariectomized mice Four Target Combination Therapy: GLP-1-GIP-GCG-IGF-1
Pay in 4 interest-free payments of $7.45 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18












![Tirzepatide vs. Semaglutide: Which Weight Loss Drug Works Better? [May 2025 NEJM Study Explained]](https://belite.com/wp-content/uploads/2025/06/July-2025-Blog-Post-Belite.png)






![DEMON SLAYER [34] SHEET STICKERS](https://cdn.shopify.com/s/files/1/0852/5253/8682/files/DEMONSLAYER34.webp?v=1718999899)




